Pfizer (PFE), a company well-known for its effective drugs and vaccines, is currently at a crucial moment with its stock priced at $25.04. The main question is whether the trendline, established since April, will continue to support the stock. This line has been tested several times over the past eight months, serving as a solid foundation for the stock’s upward movement.
If the stock stays above this trendline, it will likely continue to rise. However, if it breaks below, the stock could drop to around $21.97, which is a 12% decrease from its current price. This target is based on the stock’s past performance and the trend’s structure, suggesting it could be where the decline stops if the trendline fails.
Traders have a clear choice: bulls need to keep the trendline intact, while bears should wait for confirmation of a break. Volume during any potential drop is essential. High selling volume can indicate a true shift in market sentiment. Despite market challenges, PFE presents a straightforward technical setup where the trendline distinguishes between ongoing growth and a possible decline to the low $22 range.
As of today, December 18, 2025, Pfizer is trading around $25.04, and the stock’s eight-month uptrend is on the line. Whether the trendline holds will guide our next steps. This line is where the competition between buyers and sellers is most intense.
For those optimistic about the stock, the plan is to see the trendline hold and use it as a low-risk entry point. Options we might consider include buying January 2026 call options with a strike price around $26 or selling cash-secured puts below the trendline, such as at the $24 level. This strategy bets on a bounce from this critical support.
Supporting this view, Pfizer has recently shared positive news, including favorable Phase 2 trial results for a new antiviral drug last month. Moreover, their Q3 2025 earnings report showed a 4% revenue increase, mainly due to strong sales in their oncology division. These positive fundamentals could encourage buyers to uphold the trendline.
On the other hand, if a breakdown seems likely, patience is important. We should wait for a daily close below the trendline. A decisive break would indicate a move toward the $21.97 target, making it appealing to buy February 2026 put options. Additionally, a bear call spread above the current price could be another way to profit from a decline or stagnant movement.
Concerns about the 2026 patent cliff for one of Pfizer’s key cardiovascular drugs enhance this bearish outlook, with analysts predicting potential revenue losses of more than $3 billion each year. Compounding this issue, Eli Lilly has recently received expanded approval for its weight-loss treatment, increasing competition in Pfizer’s market area. A similar situation occurred in late 2023 when concerns about patents caused the stock to drop to multi-year lows before recovering.
Looking back, we see a significant decline of the stock after its highs in the early 2020s during the pandemic, making this current eight-month increase the most consistent recovery we’ve observed since then. A failure to maintain this trend could feel like a return to post-pandemic struggles and erase much of the progress made this year. Thus, the stakes are high, beyond just a simple technical breakdown.
Lastly, implied volatility will be an essential factor for our trading strategies in the coming days. As PFE balances on this critical point, a sharp price movement will likely increase volatility, raising options costs. We should closely monitor trading volume on any significant moves; a breakdown with high volume would provide strong evidence to support a bearish position.
here to set up a live account on VT Markets now
